Clinical Trials for Relapsed Cancer

1. Phase 2 Trial of XL184 (Cabozantinib) an Oral Small-Molecule Inhibitor of Multiple Kinases, in Children and Young Adults with Refractory Sarcomas, Wilms Tumor, and Other Rare Tumors
   Principal Investigator Suzanne Shusterman, MD
2. A Phase I Study of LY2606368, a CHK1/2 Inhibitor, in Pediatric Patients with Recurrent or Refractory Solid Tumors, including CNS Tumors
   Principal Investigator Steven DuBois, MD
3. A Phase I Study of Entinostat, an Oral Histone Deacetylase Inhibitor, in Pediatric Patients with Recurrent or Refractory Solid Tumors, including CNS Tumors and Lymphoma
   Principal Investigator Steven DuBois, MD
4. A Phase 1/2 Study of AZD1775 (MK-1775) In Combination with Oral Irinotecan in Children, Adolescents, and Young Adults with Relapsed or Refractory Solid Tumors
   Principal Investigator Steven DuBois, MD
5. Phase 1 Trial of CUDC-907 in Children and Young Adults with Relapsed or Refractory Solid Tumors, CNS Tumors, or Lymphoma
   Principal Investigator Steven DuBois, MD
6. A Phase 1, Open-Label, Dose-Escalation Study of Olaratumab as a Single Agent and in Combination with Doxorubicin, Vincristine/Irinotecan, or High-Dose Ifosfamide in Pediatric Patients with Relapsed or Refractory Solid Tumors
   Principal Investigator Steven DuBois, MD
7. A Phase I/II Study of Pembrolizumab (MK-3475) in Children with advanced melanoma or a PD-L1 positive advanced, relapsed or refractory solid tumor or lymphoma
   Principal Investigator Steven DuBois, MD
8. PNOC 002: Safety, Phase 0, and Pilot Efficacy Study of Vemurafenib, an oral inhibitor of BRAFV600E, in Children and Young Adults with Recurrent/Refractory BRAFV600E or BRAF Ins T mutant Brain Tumors
   Principal Investigator Susan Chi, MD
9. A Phase I Study of the Oral TRK Inhibitor LOXO-101 in Pediatric Patients with Advanced Solid or Primary Central Nervous System Tumors
   Principal Investigator Steven DuBois, MD
10. A Phase 1/1b, Open-Label, Dose-Escalation and Expansion Study of Entrectinib (RXDX-101) in Children and Adolescents with Recurrent or Refractory Solid Tumors and Primary CNS Tumors
    Principal Investigator Steven DuBois, MD
11. A Phase 1 Study of Selinexor (KPT-330), a Selective XPO1 Inhibitor, in Recurrent and Refractory Pediatric Solid Tumors, Including CNS Tumors
    Principal Investigator Suzanne Shusterman, MD
12. A Phase I/II, Multicenter, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Patients with Previously Treated Solid Tumors
    Principal Investigator Steven DuBois, MD
13. A Phase II Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects with INI1-Negative Tumors or Relapse or Refractory Synovial Sarcoma
    Principal Investigator Gregory Cote, MD
14. A Phase I Study of the EZH2 Inhibitor Tazemetostat in Pediatric Subjects with Relapsed or Refractory INI1-Negative Tumors or Synovial Sarcoma
    Principal Investigator Susan Chi, MD
15. Phase I-II Study of MEK162 for Children Low-Grade Gliomas and Other Ras/Raf/ERK Pathway Activated Tumors
    Principal Investigator Mark Kieran, MD
16. Phase I Open Label, Dose Escalation, Monotherapy Trial of Afatinib to Determine the MTD, Safety, PK and Efficacy of Afatinib in Children Aged 2 Years to <18 Years with Recurrent/Refractory Neuroectodermal Tumours, Rhabdomyosarcoma and Tumours with ErbB Pathway Deregulation
    Principal Investigator Mark Kieran, MD
17. An Open-Label, Dose-Escalation, Phase I/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of the MEK Inhibitor Trametinib in Children and Adolescents Subjects with Cancer or Plexiform Neurofibromas and Trametinib in Combination with Dabrafenib in Children and Adolescents with Cancers Harboring V600 Mutations>
    Principal Investigator Mark Kieran, MD
18. A Phase II Study of Cabozantinib (XL184) for Plexiform Neurofibromas in Subjects with Neurofibromatosis Type 1 Age 16 Years or Greater
    Principal Investigator Nicole Ullrich, MD
19. Phase II Study of Metronomic and Targeted Anti-Angiogenesis Therapy for Children with Recurrent/Progressive Medulloblastoma
    Principal Investigator Mark Kieran, MD
20. Open-label, Phase 2 Study of Bevacizumab in Children and Adults with Neurofibromatosis 2 and Progressive Vestibular Schwannomas That Are Poor Candidates for Standard Treatment with Surgery or Radiation
    Principal Investigator Nicole Ullrich, MD
21. Phase I/IIa, 2-Part, Multi-Center, Single-Arm, Open-Label Study to Determine the Safety, Tolerability and Pharmacokinetics of Oral Dabrafenib in Pediatric Subjects Aged 1 Month to <18 Years with Advanced BRAF V600-Mutation Positive Solid Tumors
    Principal Investigator Mark Kieran, MD

Contact us
Not sure which clinical trials might be right for your child? Email our clinical trials team at clinicaltrials@danafarberbostonchildrens.org.

1. A Phase 1/2 Study of CPX-351 (NSC# 775341; IND #129443) Alone Followed by Fludarabine, Cytarabine, and G-CSF (FLAG) for Children with Relapsed Acute Myeloid Leukemia (AML)
   Principal Investigator Andrew Place, MD
2. T2012-002: A Pilot Study of Vincristine Sulfate Liposome Injection (Marqibo®) in Combination with UK ALL R3 Induction Chemotherapy for Children, Adolescents, and Young Adults with Relapse of Acute Lymphoblastic Leukemia
   Principal Investigator Andrew Place, MD
3. Phase I study of carfilzomib in combination with cyclophosphamide and etoposide for children with relapsed and refractory solid tumors and leukemias
   Principal Investigator Steven DuBois, MD
4. Dasatinib in Combination with Chemotherapy for Relapsed or Refractory Core Binding Factor Acute Myeloid Leukemia: A Phase I Study
   Principal Investigator Andrew Place, MD
5. A Phase1b/Randomized Phase 2 Study to Evaluate LY3039478 in Combination with Dexamethasone in T-ALL/T-LBL Patients
   Principal Investigator Andrew Place, MD
6. A Phase I Trial of Temsirolimus (CCI-779, Pfizer, Inc) in Combination with Etoposide and Cyclophosphamide in Children with Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkin Lymphoma
   Principal Investigator Lewis Silverman, MD
7. Phase I Trial of the Selective Inhibitor of Nuclear Export, KPT-330, in Relapsed Childhood ALL and AML
   Principal Investigator Andrew Place, MD
8. A Phase I Trial of Autologous T-Lymphocytes Genetically Targeted to the B-Cell Specific Antigen CD19 in Pediatric and Young Adult Patients with Relapsed B-Cell ALL
   Principal Investigator Lewis Silverman, MD

Contact us
Not sure which clinical trials might be right for your child? Email our clinical trials team at clinicaltrials@danafarberbostonchildrens.org.

1. A Phase I Study of Entinostat, an Oral Histone Deacetylase Inhibitor, in Pediatric Patients with Recurrent or Refractory Solid Tumors, including CNS Tumors and Lymphoma
   Principal Investigator Steven DuBois, MD
2. A Phase 1/2 Study of Nivolumab in Children, Adolescents, and Young Adults with Recurrent or Refractory Solid Tumors as a Single Agent and in Combination with Ipilimumab
   Principal Investigator Steven DuBois, MD
3. Phase 1 Trial of CUDC-907 in Children and Young Adults with Relapsed or Refractory Solid Tumors, CNS Tumors, or Lymphoma
   Principal Investigator Steven DuBois, MD
4. A Phase I/II Study of Pembrolizumab (MK-3475) in Children with advanced melanoma or a PD-L1 positive advanced, relapsed or refractory solid tumor or lymphoma
   Principal Investigator Steven DuBois, MD
5. A Phase 1 Study of Selinexor (KPT-330), a Selective XPO1 Inhibitor, in Recurrent and Refractory Pediatric Solid Tumors, Including CNS Tumors
   Principal Investigator Suzanne Shusterman, MD
6. Phase I Study of Carfilzomib in Combination with Cyclophosphamide and Etoposide for Children with Relapsed and Refractory Solid Tumors and Leukemias
   Principal Investigator Steven DuBois, MD
7. An Early Phase, Multicenter, Open-Label Study of the Safety and Pharmacokinetics of Anti-PD-L1 Antibody (MPDL3280A) in Pediatric and Young Adult Patients with Previously Treated Solid Tumors
   Principal Investigator Steven DuBois, MD
8. An Open-Label, Dose-Escalation, Phase I/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of the MEK Inhibitor Trametinib in Children and Adolescents Subjects with Cancer or Plexiform Neurofibromas and Trametinib in Combination with Dabrafenib in Children and Adolescents with Cancers Harboring V600 Mutations
   Principal Investigator Mark Kieran, MD
9. A Phase I Trial of Temsirolimus in Combination with Etoposide and Cyclophosphamide in Children with Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkin Lymphoma
   Principal Investigator Lewis Silverman, MD

Contact us
Not sure which clinical trials might be right for your child? Email our clinical trials team at clinicaltrials@danafarberbostonchildrens.org.

1. A Phase 1 Study of LY2606368, a CHK1/2 Inhibitor, in Pediatric Patients with Recurrent or Refractory Solid Tumors, Including CNS Tumors
   Principal Investigator Steven DuBois, MD, MS
2. A Phase 1 Study of Entinostat, an Oral Histone Deacetylase Inhibitor, in Pediatric Patients with Recurrent or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
   Principal Investigator Steven DuBois, MD, MS
3. A Phase 1/2 Study of Nivolumab in Children, Adolescents, and Young Adults with Recurrent or Refractory Solid Tumors as a Single Agent and in Combination with Ipilimumab
   Principal Investigator Steven DuBois, MD
4. A Phase 1/2 Study of AZD1775 (MK-1775) In Combination with Oral Irinotecan in Children, Adolescents, and Young Adults with Relapsed or Refractory Solid Tumors
   Principal Investigator Steven DuBois, MD
5. Phase 1 Trial of CUDC-907 in Children and Young Adults with Relapsed or Refractory Solid Tumors, CNS Tumors, or Lymphoma
   Principal Investigator Steven DuBois, MD
6. A Phase 1, Open-Label, Dose-Escalation Study of Olaratumab as a Single Agent and in Combination with Doxorubicin, Vincristine/Irinotecan, or High-Dose Ifosfamide in Pediatric Patients with Relapsed or Refractory Solid Tumors
   Principal Investigator Steven DuBois, MD
7. A Phase I Study of the Oral TRK Inhibitor LOXO-101 in Pediatric Patients with Advanced Solid or Primary Central Nervous System Tumors
   Principal Investigator Steven DuBois, MD
8. A Phase 1/1b, Open-Label, Dose-Escalation and Expansion Study of Entrectinib (RXDX-101) in Children and Adolescents with Recurrent or Refractory Solid Tumors and Primary CNS Tumors
   Principal Investigator Steven DuBois, MD
9. Phase I Study of Carfilzomib in Combination with Cyclophosphamide and Etoposide for Children with Relapsed and Refractory Solid Tumors and Leukemias
   Principal Investigator Steven DuBois, MD
10. A Phase I/II, Multicenter, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Patients with Previously Treated Solid Tumors
    Principal Investigator Steven DuBois, MD
11. A Phase 1 Study of Selinexor (KPT-330), a Selective XPO1 Inhibitor, in Recurrent and Refractory Pediatric Solid Tumors, Including CNS Tumors
    Principal Investigator Suzanne Shusterman, MD
12. Phase I Open Label, Dose Escalation, Monotherapy Trial of Afatinib to Determine the MTD, Safety, PK and Efficacy of Afatinib in Children Aged 2 Years to <18 Years with Recurrent/Refractory Neuroectodermal Tumours, Rhabdomyosarcoma and Tumours with ErbB Pathway Deregulation
    Principal Investigator Mark Kieran, MD
13. An Early Phase, Multicenter, Open-Label Study of the Safety and Pharmacokinetics of Anti-PD-L1 Antibody (MPDL3280A) in Pediatric and Young Adult Patients with Previously Treated Solid Tumors
    Principal Investigator Steven DuBois, MD
14. Phase I Study of SF1126 For Patients with Relapsed or Refractory Neuroblastoma
    Principal Investigator Suzanne Shusterman, MD
15. An Open-Label, Dose-Escalation, Phase I/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of the MEK Inhibitor Trametinib in Children and Adolescents Subjects with Cancer or Plexiform Neurofibromas and Trametinib in Combination with Dabrafenib in Children and Adolescents with Cancers Harboring V600 Mutations
    Principal Investigator Mark Kieran, MD
16. A Phase I Study of Sorafenib andCyclophosphamide and Topotecan in Patients with Relapsed and RefractoryNeuroblastoma
    Principal Investigator Suzanne Shusterman, MD
17. Phase I Study of Difluoromethylornithine (DFMO) and Celecoxib with Cyclophosphamide/Topotecanfor Patients with Relapsed or Refractory Neuroblastoma
    Principal Investigator Suzanne Shusterman, MD
18. Randomized Phase II Study of131I-MIBG vs. 131I-MIBG with Vincristine and Irinotecan vs.131I-MIBG withVorinistat for Resistant/Relapsed Neuroblastoma
    Principal Investigator Suzanne Shusterman, MD
19. A Phase I, Open-label, DoseEscalation Study of LDK378 in Pediatric Patients with Malignancies That Have aGenetic Alteration in Anaplastic Lymphoma Kinase (ALK)
    Principal Investigator Suzanne Shusterman, MD
20. A Phase II Randomized Trial of Irinotecan/Temozolomide with Temsirolimus or Chimeric 14.18 Antibody in Children with Refractory, Relapsed or Progressive Neuroblastoma
    Principal Investigator Suzanne Shusterman
21. A Phase I Study of Lenalidomide and Anti-GD2 Mab Ch14.18 with or without Isotretinoin in Patients with Refractory/Recurrent Neuroblastoma
    Principal Investigator Suzanne Shusterman, MD
22. An Open Label, Expanded Access Protocol Using 131I-metaiodobenzylguanidine (131I-MIBG) Therapy in Patients with Refractory Neuroblastoma, Pheochromocytoma, or Paraganglioma
    Principal Investigator Suzanne Shusterman, MD

Contact us
Not sure which clinical trials might be right for your child? Email our clinical trials team at clinicaltrials@danafarberbostonchildrens.org.

1. Phase II Trial of XL184 (Cabozantinib) an Oral Small-Molecule Inhibitor of Multiple Kinases, in Children and Young Adults with Refractory Sarcomas, Wilms Tumor, and Other Rare Tumors
   Principal Investigator Suzanne Shusterman, MD
2. A Phase 1 Study of LY2606368, a CHK1/2 Inhibitor, in Pediatric Patients with Recurrent or Refractory Solid Tumors, Including CNS Tumors
   Principal Investigator Steven DuBois, MD, MS
3. A Phase 1 Study of Entinostat, an Oral Histone Deacetylase Inhibitor, in Pediatric Patients with Recurrent or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
   Principal Investigator Steven DuBois, MD, MS
4. A Phase 1/2 Study of Nivolumab in Children, Adolescents, and Young Adults with Recurrent or Refractory Solid Tumors as a Single Agent and in Combination with Ipilimumab
   Principal Investigator Steven DuBois, MD
5. A Phase 1/2 Study of AZD1775 (MK-1775) In Combination with Oral Irinotecan in Children, Adolescents, and Young Adults with Relapsed or Refractory Solid Tumors
   Principal Investigator Steven DuBois, MD
6. Phase 1 Trial of CUDC-907 in Children and Young Adults with Relapsed or Refractory Solid Tumors, CNS Tumors, or Lymphoma
   Principal Investigator Steven DuBois, MD
7. A Phase I/II Study of Pembrolizumab (MK-3475) in Children with advanced melanoma or a PD-L1 positive advanced, relapsed or refractory solid tumor or lymphoma
   Principal Investigator Steven DuBois, MD
8. A Phase 1, Open-Label, Dose-Escalation Study of Olaratumab as a Single Agent and in Combination with Doxorubicin, Vincristine/Irinotecan, or High-Dose Ifosfamide in Pediatric Patients with Relapsed or Refractory Solid Tumors
   Principal Investigator Steven DuBois, MD
9. A Phase I Study of the Oral TRK Inhibitor LOXO-101 in Pediatric Patients with Advanced Solid or Primary Central Nervous System Tumors
   Principal Investigator Steven DuBois, MD
10. A Phase 1/1b, Open-Label, Dose-Escalation and Expansion Study of Entrectinib (RXDX-101) in Children and Adolescents with Recurrent or Refractory Solid Tumors and Primary CNS Tumors
    Principal Investigator Steven DuBois, MD
11. Phase I Study of Carfilzomib in Combination with Cyclophosphamide and Etoposide for Children with Relapsed and Refractory Solid Tumors and Leukemias
    Principal Investigator Steven DuBois, MD
12. A Phase I/II, Multicenter, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Patients with Previously Treated Solid Tumors
    Principal Investigator Steven DuBois, MD
13. A Phase 1 Study of Selinexor (KPT-330), a Selective XPO1 Inhibitor, in Recurrent and Refractory Pediatric Solid Tumors, Including CNS Tumors
    Principal Investigator Suzanne Shusterman, MD
14. Phase I Open Label, Dose Escalation, Monotherapy Trial of Afatinib to Determine the MTD, Safety, PK and Efficacy of Afatinib in Children Aged 2 Years to <18 Years with Recurrent/Refractory Neuroectodermal Tumours, Rhabdomyosarcoma and Tumours with ErbB Pathway Deregulation
    Principal Investigator Mark Kieran, MD
15. An Early Phase, Multicenter, Open-Label Study of the Safety and Pharmacokinetics of Anti-PD-L1 Antibody (MPDL3280A) In Pediatric and Young Adult Patients with Previously Treated Solid Tumors
    Principal Investigator Steven DuBois, MD
16. An Open-Label, Dose-Escalation, Phase I/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of the MEK Inhibitor Trametinib in Children and Adolescents Subjects with Cancer or Plexiform Neurofibromas and Trametinib in Combination with Dabrafenib in Children and Adolescents with Cancers Harboring V600 Mutations
    Principal Investigator Mark Kieran, MD
17. A Phase I, Open-label, Dose Escalation Study of LDK378 in Pediatric Patients with Malignancies That Have a Genetic Alteration in Anaplastic Lymphoma Kinase (ALK)
    Principal Investigator Suzanne Shusterman, MD
18. Phase I Study of Olaparib with Irinotecan and/or Temezolomide in Adolescent and Adult Patients with Recurrent/Metastatic Ewing’s Sarcoma Following Failure of Prior Chemotherapy
    Principal Investigator Steven DuBois, MD
19. An Open Label, Expanded Access Protocol Using 131I-metaiodobenzylguanidine (131I-MIBG) Therapy in Patients with Refractory Neuroblastoma, Pheochromocytoma, or Paraganglioma
    Principal Investigator Suzanne Shusterman, MD

Contact us
Not sure which clinical trials might be right for your child? Email our clinical trials team at clinicaltrials@danafarberbostonchildrens.org.

1. Phase 2 Trial of XL184 (Cabozantinib) an Oral Small-Molecule Inhibitor of Multiple Kinases, in Children and Young Adults with Refractory Sarcomas, Wilms Tumor, and Other Rare Tumors
   Principal Investigator Suzanne Shusterman, MD
2. A Phase 1 Study of LY2606368, a CHK1/2 Inhibitor, in Pediatric Patients with Recurrent or Refractory Solid Tumors, Including CNS Tumors
   Principal Investigator Steven DuBois, MD, MS
3. A Phase 1 Study of Entinostat, an Oral Histone Deacetylase Inhibitor, in Pediatric Patients with Recurrent or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
   Principal Investigator Steven DuBois, MD, MS
4. Phase 1/2 Study of Nivolumab in Children, Adolescents, and Young Adults with Recurrent or Refractory Solid Tumors as a Single Agent and in Combination with Ipilimumab
   Principal Investigator Steven DuBois, MD
5. A Phase 1/2 Study of AZD1775 (MK-1775) In Combination with Oral Irinotecan in Children, Adolescents, and Young Adults with Relapsed or Refractory Solid Tumors
   Principal Investigator Steven DuBois, MD
6. Phase 1 Trial of CUDC-907 in Children and Young Adults with Relapsed or Refractory Solid Tumors, CNS Tumors, or Lymphoma
   Principal Investigator Steven DuBois, MD
7. A Phase I/II Study of Pembrolizumab (MK-3475) in Children with Advanced Melanoma or a PD-L1 Positive Advanced, Relapsed or Refractory Solid Tumor or Lymphoma
   Principal Investigator Steven DuBois, MD
8. A Phase 1, Open-Label, Dose-Escalation Study of Olaratumab as a Single Agent and in Combination with Doxorubicin, Vincristine/Irinotecan, or High-Dose Ifosfamide in Pediatric Patients with Relapsed or Refractory Solid Tumors
   Principal Investigator Steven DuBois, MD
9. A Phase I Study of the Oral TRK Inhibitor LOXO-101 in Pediatric Patients with Advanced Solid or Primary Central Nervous System Tumors
   Principal Investigator Steven DuBois, MD
10. A Phase 1/1b, Open-Label, Dose-Escalation and Expansion Study of Entrectinib (RXDX-101) in Children and Adolescents with Recurrent or Refractory Solid Tumors and Primary CNS Tumors
    Principal Investigator Steven DuBois, MD
11. An Open-label, Multi-center, Phase 2 Study of Denosumab in Subjects with Giant Cell Tumor of Bone
    Principal Investigator Katherine Janeway, MD
12. A Phase 1 Study of Selinexor, a Selective XPO1 Inhibitor, in Recurrent and Refractory Pediatric Solid Tumors, Including CNS Tumors
    Principal Investigator Suzanne Shusterman, MD
13. A Phase I/II, Multicenter, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Patients with Previously Treated Solid Tumors
    Principal Investigator Steven DuBois, MD
14. A Phase II Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects with INI1-Negative Tumors or Relapse or Refractory Synovial Sarcoma
    Principal Investigator Gregory Cote, MD
15. A Phase I Study of the EZH2 Inhibitor Tazemetostat in Pediatric Subjects with Relapse or Refractory INI1-Negative Tumors or Synovial Sarcoma
    Principal Investigator Susan Chi, MD
16. An Early Phase, Multicenter, Open-Label Study of the Safety and Pharmacokinetics of Anti-PD-L1 Antibody (MPDL3280A) in Pediatric and Young Adult Patients with Previously Treated Solid Tumors
    Principal Investigator Steven DuBois, MD
17. An Open-Label, Dose-Escalation, Phase I/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of the MEK Inhibitor Trametinib in Children and Adolescents Subjects with Cancer or Plexiform Neurofibromas and Trametinib in Combination with Dabrafenib in Children and Adolescents with Cancers Harboring V600 Mutations
    Principal Investigator Mark Kieran, MD
18. A Phase I, Open-label, Dose Escalation Study of LDK378 in Pediatric Patients with Malignancies That Have a Genetic Alteration in Anaplastic Lymphoma Kinase (ALK)
    Principal Investigator Suzanne Shusterman, MD
19. Phase I Study of Olaparib with Irinotecan and/or Temozolomide in Adolescent and Adult Patients with Recurrent/Metastatic Ewing's Sarcoma Following Failure of Prior Chemotherapy
    Principal Investigator Steven DuBois, MD

Contact us
Not sure which clinical trials might be right for your child? Email our clinical trials team at clinicaltrials@danafarberbostonchildrens.org.

1. A Phase I Trial of Autologous T-Lymphocytes (CAR T-Cell) Genetically Targeted to the B-Cell Specific Antigen CD19 in Pediatric and Young Adult Patients with Relapsed B-Cell Acute Lymphoblastic Leukemia
   Principal Investigator Lewis Silverman

Contact us
Not sure which clinical trials might be right for your child? Email our clinical trials team at clinicaltrials@danafarberbostonchildrens.org.